Published in Leuk Res Treatment on February 06, 2012
Human T-lymphotropic Virus Type I (HTLV-I) Proviral Load and Clinical Features in Iranian HAM/TSP Patients: Comparison of HTLV-I Proviral Load in HAM/TSP Patients. Iran J Basic Med Sci (2013) 0.85
Human T Lymphotropic Virus Type I (HTLV-I) Oncogenesis: Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma (ATL). Iran J Basic Med Sci (2013) 0.81
Functional activity of monocytes and macrophages in HTLV-1 infected subjects. PLoS Negl Trop Dis (2014) 0.78
HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Is Not Associated with SNP rs12979860 of the IL-28B Gene. Mediators Inflamm (2015) 0.76
Postrenal Transplant Human T-Cell Lymphotropic Virus Type I-Associated Myelopathy/Tropical Spastic Paraparesis: A Case Report and Review of the Literature. Transplant Direct (2015) 0.75
Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net). Orphanet J Rare Dis (2016) 0.75
HTLV-1 Infection and Neuropathogenesis in the Context of Rag1(-/-)γc(-/-) (RAG1-Hu) and BLT Mice. J Neuroimmune Pharmacol (2017) 0.75
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet (1985) 13.47
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A (1981) 11.92
hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem (1993) 11.44
HTLV-I associated myelopathy, a new clinical entity. Lancet (1986) 10.49
Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev (2006) 10.24
Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A (1984) 4.97
Global epidemiology of HTLV-I infection and associated diseases. Oncogene (2005) 4.77
Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. EMBO J (1986) 4.58
Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis (2007) 3.80
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol (1998) 3.32
HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A (2006) 3.11
The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol (2002) 3.01
HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A (1999) 2.45
Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol (1991) 2.27
Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol (2010) 2.27
Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med (2002) 2.14
The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood (2011) 2.11
Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med (2008) 2.07
Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer (2004) 2.04
Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol (1997) 1.99
Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology (1988) 1.96
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A (1998) 1.95
Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood (2000) 1.87
Phylogenetic subgroups of human T cell lymphotropic virus (HTLV) type I in the tax gene and their association with different risks for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis (2000) 1.80
Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene (2005) 1.74
The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol (2000) 1.73
Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene (2010) 1.67
New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol (2010) 1.67
An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses (1993) 1.66
Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol (2006) 1.66
In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology (2009) 1.58
Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP). J Neurol Sci (1990) 1.56
HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog (2011) 1.53
Mother-to-child transmission of human T-cell leukemia virus type-I. Jpn J Cancer Res (1985) 1.53
The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer (1990) 1.51
Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest (2005) 1.46
Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. AIDS Res Hum Retroviruses (1992) 1.45
High frequency of CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood (2007) 1.43
HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol (1995) 1.39
Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis (2002) 1.39
Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology (1996) 1.32
Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis. J Neurovirol (1996) 1.29
HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog (2010) 1.28
Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J (1987) 1.27
Reduced Foxp3 protein expression is associated with inflammatory disease during human t lymphotropic virus type 1 Infection. J Infect Dis (2006) 1.22
High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Blood (2002) 1.20
Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I. J Immunol (2004) 1.20
Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis (1999) 1.15
The immune response to HTLV-I. Curr Opin Immunol (2000) 1.14
Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. Ann Neurol (1990) 1.12
A prospective study of sexual transmission of human T lymphotropic virus (HTLV)-I and HTLV-II. J Infect Dis (2005) 1.12
APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J Virol (2010) 1.12
Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol (2003) 1.12
Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis (2002) 1.08
Envelope proteins of human T-cell leukemia virus: expression in Escherichia coli and its application to studies of env gene functions. Proc Natl Acad Sci U S A (1984) 1.06
Human T cell lymphotropic virus (HTLV) type-1-specific CD8+ T cells: frequency and immunodominance hierarchy. J Infect Dis (2004) 1.04
Protection of cynomolgus monkeys against infection by human T-cell leukemia virus type-I by immunization with viral env gene products produced in Escherichia coli. Int J Cancer (1987) 1.04
Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. J Immunol (2010) 1.02
Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease. Blood (2008) 1.02
Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization. J Virol (1994) 1.00
In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. J Infect Dis (2011) 1.00
SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness. J Neurovirol (2006) 1.00
The avidity and lytic efficiency of the CTL response to HTLV-1. J Immunol (2009) 0.99
Differential immune responsiveness to the immunodominant epitopes of regulatory proteins (tax and rex) in human T cell lymphotropic virus type I-associated myelopathy. J Infect Dis (1994) 0.99
Milk-borne transmission of HTLV-I from carrier mothers to their children. Jpn J Cancer Res (1987) 0.97
DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells. J Virol (2009) 0.97
HTLV-I-associated myelopathy. Neuropathology (2000) 0.96
Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells. Virulence (2011) 0.95
Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood (2009) 0.94
Risk factors and cofactors for human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica. Am J Epidemiol (1995) 0.93
Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Infect Dis (2004) 0.93
What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus? Immunol Rev (1997) 0.93
Persistent paradox of natural history of human T lymphotropic virus type I: parallel analyses of Japanese and Jamaican carriers. J Infect Dis (2004) 0.92
Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol (2009) 0.91
IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population. Immunology (2009) 0.91
Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol Scand (1992) 0.90
Natural killer (NK) cells in HTLV-I-associated myelopathy/tropical spastic paraparesis-decrease in NK cell subset populations and activity in HTLV-I seropositive individuals. J Neuroimmunol (1991) 0.89
Monocytes from HTLV-1-infected patients are unable to fully mature into dendritic cells. Blood (2010) 0.89
In vitro modulation of lymphocyte proliferation by prednisolone and interferon-alpha in patients with HTLV-I-associated myelopathy (HAM). J Neuroimmunol (1989) 0.89
Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis (2002) 0.88
Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system. Acta Neuropathol (2000) 0.88
Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-I-associated myelopathy. J Neuroimmunol (2008) 0.88
The clinical and pathological features of peripheral neuropathy accompanied with HTLV-I associated myelopathy. J Neurol Sci (2003) 0.87
Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease. J Leukoc Biol (2009) 0.87
Lower numbers of circulating Natural Killer T (NK T) cells in individuals with human T lymphotropic virus type 1 (HTLV-1) associated neurological disease. Clin Exp Immunol (2009) 0.86
A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Neurol Sci (2005) 0.86
Prevention of human T cell lymphotropic virus type I infection in Japanese macaques by passive immunization. Leukemia (1996) 0.85
Association of CD40 ligand expression on HTLV-I-infected T cells and maturation of dendritic cells. Scand J Immunol (2001) 0.85
Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriers. Blood (2003) 0.84
Association of HTLV-I antibody profile of asymptomatic carriers with proviral DNA levels of peripheral blood mononuclear cells. J Acquir Immune Defic Syndr (1994) 0.84
Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. Clin Diagn Lab Immunol (1999) 0.84
Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science (2003) 5.19
The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood (2011) 2.11
Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol (2007) 1.76
HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog (2008) 1.45
Human T-lymphotropic virus, type 1, tax protein triggers microtubule reorientation in the virological synapse. J Biol Chem (2005) 1.45
Lymphocyte kinetics: the interpretation of labelling data. Trends Immunol (2002) 1.44
Engagement of specific T-cell surface molecules regulates cytoskeletal polarization in HTLV-1-infected lymphocytes. Blood (2005) 1.44
High frequency of CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood (2007) 1.43
In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc Natl Acad Sci U S A (2007) 1.36
Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics (2012) 1.35
Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis (2009) 1.29
HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog (2010) 1.28
A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol (2005) 1.25
High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Blood (2002) 1.20
Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I. J Immunol (2004) 1.20
Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNAs. Blood (2011) 1.18
Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology (2006) 1.17
Human T-lymphotropic virus-1 visualized at the virological synapse by electron tomography. PLoS One (2008) 1.16
HTLV-1-Tax and ICAM-1 act on T-cell signal pathways to polarize the microtubule-organizing center at the virological synapse. Blood (2009) 1.12
HTLV-1-infected T cells contain a single integrated provirus in natural infection. Blood (2012) 1.11
Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis (2002) 1.08
Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood (2010) 1.05
FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. Int J Cancer (2009) 1.05
Human T cell lymphotropic virus (HTLV) type-1-specific CD8+ T cells: frequency and immunodominance hierarchy. J Infect Dis (2004) 1.04
Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection. PLoS Pathog (2013) 1.04
Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog (2012) 1.03
Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. J Immunol (2010) 1.02
KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection. PLoS Pathog (2011) 1.02
In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. J Infect Dis (2011) 1.00
T-cell epitope prediction: rescaling can mask biological variation between MHC molecules. PLoS Comput Biol (2009) 0.99
The avidity and lytic efficiency of the CTL response to HTLV-1. J Immunol (2009) 0.99
Quantification of the virus-host interaction in human T lymphotropic virus I infection. Retrovirology (2005) 0.99
Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood (2011) 0.97
HTLV-1 propels thymic human T cell development in "human immune system" Rag2⁻/⁻ gamma c⁻/⁻ mice. PLoS Pathog (2011) 0.96
Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis (2012) 0.95
Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Infect Dis (2004) 0.93
How does HTLV-I persist despite a strong cell-mediated immune response? Trends Immunol (2007) 0.93
Activation of interleukin-13 expression in T cells from HTLV-1-infected individuals and in chronically infected cell lines. Blood (2003) 0.93
Quantifying HTLV-I dynamics. Immunol Cell Biol (2007) 0.92
The dynamics of T-cell fratricide: application of a robust approach to mathematical modelling in immunology. J Theor Biol (2003) 0.91
Plasma proteome analysis in HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology (2011) 0.91
Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients' T cells by the viral Tax oncoprotein. Blood (2008) 0.88
The HTLV-1 Virological Synapse. Viruses (2010) 0.88
Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis (2002) 0.88
Conference highlights of the 15th International Conference on Human Retrovirology: HTLV and related retroviruses, 4-8 June 2011, Leuven, Gembloux, Belgium. Retrovirology (2011) 0.87
Cell-mediated immune response to human T-lymphotropic virus type I. Viral Immunol (2005) 0.86
Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo. PLoS Pathog (2013) 0.86
Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriers. Blood (2003) 0.84
The protean immune cell synapse: a supramolecular structure with many functions. Semin Immunol (2003) 0.83
Is There a Role for HTLV-1-Specific CTL in Adult T-Cell Leukemia/Lymphoma? Leuk Res Treatment (2011) 0.82
An introduction to lymphocyte and viral dynamics: the power and limitations of mathematical analysis. Proc Biol Sci (2003) 0.81
Presentation of a new H-2D(k)-restricted epitope in the Tax protein of human T-lymphotropic virus type I is enhanced by the proteasome inhibitor lactacystin. J Gen Virol (2002) 0.80
HTLV-1 infection: what determines the risk of inflammatory disease? Trends Microbiol (2012) 0.79
Ex vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptide. J Infect Dis (2007) 0.78
HTLV-1 Infection and Its Associated Diseases. Leuk Res Treatment (2012) 0.78
Balancing the robustness and predictive performance of biomarkers. J Comput Biol (2013) 0.78
Genetic variability in the extracellular matrix protein as a determinant of risk for developing HTLV-I-associated neurological disease. Immunogenetics (2006) 0.75